The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Tradename to be confirmed Vertex Pharmaceuticals Australia Pty Ltd
Product name
Tradename to be confirmed
Accepted date
Sep-2024
Active ingredients
deutivacaftor, tezacaftor, vanzacaftor
Proposed indication
Treatment of cystic fibrosis in people aged 6 years and older who have at least one responsive mutation in the cystic fibrosis gene (CFTR).
Application type
B (new combination)
Publication date
Sep-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.